Imprimis spins out a new biotech focused on eye drugs; Alzheimer’s groups back PhII study at Amylyx
→ San Diego-based Imprimis has set up a new subsidiary to pursue the development of new drugs for eye diseases. And the company has tapped …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
